Data Insights

Soquelitinib by Corvus Pharmaceuticals for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval

Soquelitinib is under clinical development by Corvus Pharmaceuticals and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in Atopic Dermatitis (Atopic Eczema)

Data Insights

Mupadolimab by Corvus Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Mupadolimab by Corvus Pharmaceuticals for Uterine Cancer: Likelihood of Approval

Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Uterine Cancer

Data Insights

Mupadolimab by Corvus Pharmaceuticals for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Kidney Cancer (Renal Cell Cancer)

Data Insights

Mupadolimab by Corvus Pharmaceuticals for Endometrial Cancer: Likelihood of Approval

Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Endometrial Cancer

Data Insights

Mupadolimab by Corvus Pharmaceuticals for Sarcomas: Likelihood of Approval

Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Sarcomas. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Sarcomas

Data Insights

Mupadolimab by Corvus Pharmaceuticals for Bladder Cancer: Likelihood of Approval

Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Bladder Cancer

Data Insights

Mupadolimab by Corvus Pharmaceuticals for Cervical Cancer: Likelihood of Approval

Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Cervical Cancer

Data Insights

Mupadolimab by Corvus Pharmaceuticals for Colorectal Cancer: Likelihood of Approval

Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Colorectal Cancer

Data Insights

Ciforadenant by Corvus Pharmaceuticals for Uterine Cancer: Likelihood of Approval

Ciforadenant is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ciforadenant in Uterine Cancer

Data Insights

Ciforadenant by Corvus Pharmaceuticals for Endometrial Cancer: Likelihood of Approval

Ciforadenant is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ciforadenant in Endometrial Cancer

Data Insights

Ciforadenant by Corvus Pharmaceuticals for Sarcomas: Likelihood of Approval

Ciforadenant is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Sarcomas. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ciforadenant in Sarcomas

Data Insights

Ciforadenant by Corvus Pharmaceuticals for Cervical Cancer: Likelihood of Approval

Ciforadenant is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ciforadenant in Cervical Cancer

Data Insights

Mupadolimab by Corvus Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval

Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mupadolimab in Pancreatic Cancer

Data Insights

Soquelitinib by Corvus Pharmaceuticals for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Soquelitinib is under clinical development by Corvus Pharmaceuticals and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

Soquelitinib by Corvus Pharmaceuticals for T-Cell Lymphomas: Likelihood of Approval

Soquelitinib is under clinical development by Corvus Pharmaceuticals and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Soquelitinib in T-Cell Lymphomas

Data Insights

Soquelitinib by Corvus Pharmaceuticals for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

Soquelitinib is under clinical development by Corvus Pharmaceuticals and currently in Phase III for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According...

Data Insights

Soquelitinib by Corvus Pharmaceuticals for Follicular Lymphoma: Likelihood of Approval

Soquelitinib is under clinical development by Corvus Pharmaceuticals and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase...

Data Insights

Soquelitinib by Corvus Pharmaceuticals for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

Soquelitinib is under clinical development by Corvus Pharmaceuticals and currently in Phase III for Anaplastic Large Cell Lymphoma (ALCL). According...

Data Insights

Ciforadenant by Corvus Pharmaceuticals for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Ciforadenant is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...